{"protocolSection":{"identificationModule":{"nctId":"NCT02288273","orgStudyIdInfo":{"id":"D5551L00006"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.","officialTitle":"A Randomized Double-blind, Parallel-group Study to Evaluate the Effect of BYDUREON Compared With Placebo on 24-hour Glucose Control in Metformin-treated Patients With Type 2 Diabetes"},"statusModule":{"statusVerifiedDate":"2016-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-12"},"primaryCompletionDateStruct":{"date":"2015-08","type":"ACTUAL"},"completionDateStruct":{"date":"2015-08","type":"ACTUAL"},"studyFirstSubmitDate":"2014-11-07","studyFirstSubmitQcDate":"2014-11-07","studyFirstPostDateStruct":{"date":"2014-11-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-03-23","resultsFirstSubmitQcDate":"2016-12-05","resultsFirstPostDateStruct":{"date":"2017-01-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-12-05","lastUpdatePostDateStruct":{"date":"2017-01-27","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.","detailedDescription":"A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in 110 Metformin-treated Patients with Type 2 Diabetes"},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":239,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Bydureon","type":"EXPERIMENTAL","description":"Once weekly injected exenatide","interventionNames":["Drug: Bydureon"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo comparator","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Bydureon","description":"Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.","armGroupLabels":["Bydureon"],"otherNames":["exenatide"]},{"type":"DRUG","name":"Placebo","description":"Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in 24-hour Mean Weighted Glucose","description":"Change in 24-hour mean weighted glucose from baseline (Day -1/1) to Day 6 of Week 4 (Day 27/28) and to Day 6 of Week 10 (Day 69/70).","timeFrame":"Day 27/28"}],"secondaryOutcomes":[{"measure":"Change in 24-hour Mean Weighted Glucose Between Day 1 of Week 10 (Day 64/65) and Day 6 of Week 10 (Day 69/70) Within Each EQW-treated Patient","timeFrame":"Day 64/65"},{"measure":"Change From Baseline (Day1) to Day 70 and Day 22 in FPG","timeFrame":"Day 22/Day70"},{"measure":"Change From Baseline (Day -1) to Day 64 and Day 22 in 2- Hour Mean Weighted PPG (After the Breakfast Meal)","timeFrame":"Day 22 and Day 64"},{"measure":"Average of Change in 24-hour Mean Weighted Glucose From Baseline to Week 4 and Baseline to Week 10","timeFrame":"Week 4 and Week 10"},{"measure":"Change in HbA1c From Baseline to Day 22 and Baseline to Day 70","timeFrame":"Day 22 and Day 70"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus (T2DM) treated with stable dose of metformin \\> or = to 1500mg/day as monotherapy for at least 8 weeks\n* Hemoglobin A1c (HbA1c) 7% to 10% at screening\n* Body mass index (BMI) \\< or = to 45 kg/m2\n\nExclusion Criteria:\n\n* History of taking antihyperglycemic therapy other than metformin or metformin extended release (XR) during the 8 weeks prior to screening\n* History of taking a dipeptidyl peptidase-4 (DPP-4) inhibitor or pramlintide during 12 weeks prior to screening\n* History of potent, inhaled or intrapulmonary steroids 3 months prior to screening or during the study\n* History of prescription or over the counter weight loss medication during 3 months prior to screening\n* Previous exposure to exenatide or any glucagon-like peptide-1 (GLP-1) receptor agonist during 6 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Research Site","city":"Anaheim","state":"California","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Research Site","city":"Chino","state":"California","country":"United States","geoPoint":{"lat":34.01223,"lon":-117.68894}},{"facility":"Research Site","city":"Los Angeles","state":"California","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"North Hollywood","state":"California","country":"United States","geoPoint":{"lat":34.17223,"lon":-118.37897}},{"facility":"Research Site","city":"Santa Ana","state":"California","country":"United States","geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"Research Site","city":"Spring Valley","state":"California","country":"United States","geoPoint":{"lat":32.74477,"lon":-116.99892}},{"facility":"Research Site","city":"Tustin","state":"California","country":"United States","geoPoint":{"lat":33.74585,"lon":-117.82617}},{"facility":"Research Site","city":"Walnut Creek","state":"California","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Research Site","city":"Hollywood","state":"Florida","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Research Site","city":"Miami","state":"Florida","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Research Site","city":"Port Orange","state":"Florida","country":"United States","geoPoint":{"lat":29.13832,"lon":-80.99561}},{"facility":"Research Site","city":"Marietta","state":"Georgia","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"Research Site","city":"Chicago","state":"Illinois","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Research Site","city":"Edina","state":"Minnesota","country":"United States","geoPoint":{"lat":44.88969,"lon":-93.34995}},{"facility":"Research Site","city":"St Louis","state":"Missouri","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Research Site","city":"Butte","state":"Montana","country":"United States","geoPoint":{"lat":46.00382,"lon":-112.53474}},{"facility":"Research Site","city":"Las Vegas","state":"Nevada","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Research Site","city":"Franklin","state":"Ohio","country":"United States","geoPoint":{"lat":39.55895,"lon":-84.30411}},{"facility":"Research Site","city":"Marion","state":"Ohio","country":"United States","geoPoint":{"lat":40.58867,"lon":-83.12852}},{"facility":"Research Site","city":"Oklahoma City","state":"Oklahoma","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Research Site","city":"Mt. Pleasant","state":"South Carolina","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"Research Site","city":"Rapid City","state":"South Dakota","country":"United States","geoPoint":{"lat":44.08054,"lon":-103.23101}},{"facility":"Research Site","city":"Corpus Christi","state":"Texas","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"Research Site","city":"Houston","state":"Texas","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"Katy","state":"Texas","country":"United States","geoPoint":{"lat":29.78579,"lon":-95.8244}},{"facility":"Research Site","city":"Salt Lake City","state":"Utah","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Research Site","city":"Burke","state":"Virginia","country":"United States","geoPoint":{"lat":38.79345,"lon":-77.27165}},{"facility":"Research Site","city":"Manassas","state":"Virginia","country":"United States","geoPoint":{"lat":38.75095,"lon":-77.47527}},{"facility":"Research Site","city":"Olympia","state":"Washington","country":"United States","geoPoint":{"lat":47.04491,"lon":-122.90169}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"239 subjects were screened in order to randomize 117 subjects; however, 116 subjects were included in the modified intent to treat population, which consisted of all randomized patients who received at least one dose of randomized study drug.","groups":[{"id":"FG000","title":"Once Weekly (EQW) + Met","description":"Bydureon EQW + Metformin XR 1500-2000 mg"},{"id":"FG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"56"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"48"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"239 subjects were screened in order to randomize 117 subjects; however, 116 subjects were included in the modified intent to treat population, which consisted of all randomized patients who received at least one dose of randomized study drug.","groups":[{"id":"BG000","title":"Once Weekly (EQW) + Met","description":"Bydureon EQW + Metformin XR 1500-2000 mg"},{"id":"BG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"116"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55","spread":"10.63"},{"groupId":"BG001","value":"56","spread":"9.80"},{"groupId":"BG002","value":"55.6","spread":"10.21"}]}]}]},{"title":"Gender","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"51"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"65"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in 24-hour Mean Weighted Glucose","description":"Change in 24-hour mean weighted glucose from baseline (Day -1/1) to Day 6 of Week 4 (Day 27/28) and to Day 6 of Week 10 (Day 69/70).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"(mg/dL)","timeFrame":"Day 27/28","typeUnitsAnalyzed":"(mg/dL)","denomUnitsSelected":"(mg/dL)","groups":[{"id":"OG000","title":"EQW + Met","description":"Bydureon EQW + Metformin 1500-2000 mg"},{"id":"OG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"56"}]},{"units":"(mg/dL)","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Baseline (Day -1/1)","categories":[{"measurements":[{"groupId":"OG000","value":"185.7","spread":"41.99"},{"groupId":"OG001","value":"183.8","spread":"42.59"}]}]},{"title":"Day 27/28","categories":[{"measurements":[{"groupId":"OG000","value":"158.3","spread":"35.72"},{"groupId":"OG001","value":"176.9","spread":"44.03"}]}]},{"title":"Change from Baseline to Day 27/28","categories":[{"measurements":[{"groupId":"OG000","value":"-26.0","spread":"3.58"},{"groupId":"OG001","value":"-5.3","spread":"3.85"}]}]},{"title":"Change from Baseline to Day 69/70","categories":[{"measurements":[{"groupId":"OG000","value":"-30.8","spread":"4.54"},{"groupId":"OG001","value":"-3.0","spread":"4.78"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in 24-hour Mean Weighted Glucose Between Day 1 of Week 10 (Day 64/65) and Day 6 of Week 10 (Day 69/70) Within Each EQW-treated Patient","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Day 64/65","groups":[{"id":"OG000","title":"EQW + Met","description":"Bydureon EQW + Metformin 1500-2000 mg"},{"id":"OG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"3.46"},{"groupId":"OG001","value":"-6.9","spread":"3.68"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Day1) to Day 70 and Day 22 in FPG","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Day 22/Day70","groups":[{"id":"OG000","title":"EQW + Met","description":"Bydureon EQW + Metformin 1500-2000 mg"},{"id":"OG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Baseline to Day 22","categories":[{"measurements":[{"groupId":"OG000","value":"-29.6","spread":"4.85"},{"groupId":"OG001","value":"-1.9","spread":"4.99"}]}]},{"title":"Baseline to Day 70","categories":[{"measurements":[{"groupId":"OG000","value":"-41.9","spread":"5.21"},{"groupId":"OG001","value":"-5.0","spread":"5.53"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Day -1) to Day 64 and Day 22 in 2- Hour Mean Weighted PPG (After the Breakfast Meal)","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Day 22 and Day 64","groups":[{"id":"OG000","title":"EQW + Met","description":"Bydureon EQW + Metformin 1500-2000 mg"},{"id":"OG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Baseline to Day 22","categories":[{"measurements":[{"groupId":"OG000","value":"-32.1","spread":"5.30"},{"groupId":"OG001","value":"-2.0","spread":"5.51"}]}]},{"title":"Baseline to Day 64","categories":[{"measurements":[{"groupId":"OG000","value":"-44.4","spread":"5.62"},{"groupId":"OG001","value":"-6.0","spread":"6.12"}]}]}]},{"type":"SECONDARY","title":"Average of Change in 24-hour Mean Weighted Glucose From Baseline to Week 4 and Baseline to Week 10","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Week 4 and Week 10","groups":[{"id":"OG000","title":"EQW + Met","description":"Bydureon EQW + Metformin 1500-2000 mg"},{"id":"OG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Change in mean weighted glucose baseline to Week 4","categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"1.09"},{"groupId":"OG001","value":"-1.8","spread":"1.13"}]}]},{"title":"Change in mean weighted glucose baseline - Week 10","categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":"1.31"},{"groupId":"OG001","value":"0.7","spread":"1.36"}]}]},{"title":"Change in MAGE (mg/dL) from baseline to Week 4","categories":[{"measurements":[{"groupId":"OG000","value":"-8.2","spread":"3.13"},{"groupId":"OG001","value":"-3.8","spread":"3.25"}]}]},{"title":"Change in MAGE (mg/dL) from baseline to Week 10","categories":[{"measurements":[{"groupId":"OG000","value":"-15.2","spread":"3.51"},{"groupId":"OG001","value":"2.9","spread":"3.62"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Day 22 and Baseline to Day 70","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"% Alc","timeFrame":"Day 22 and Day 70","groups":[{"id":"OG000","title":"EQW + Met","description":"Bydureon EQW + Metformin 1500-2000 mg"},{"id":"OG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Change from baseline to Day 22","categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"0.045"},{"groupId":"OG001","value":"-0.10","spread":"0.047"}]}]},{"title":"Change from baseline to Day 70","categories":[{"measurements":[{"groupId":"OG000","value":"-0.92","spread":"0.102"},{"groupId":"OG001","value":"-0.20","spread":"0.108"}]}]}]},{"type":"SECONDARY","title":"Average of Change in 24-hour Mean Weighted Glucose From Baseline to Week 4 and Baseline to Week 10","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"% times patients had specific CGM/24-hr","timeFrame":"Week 4 and Week 10","groups":[{"id":"OG000","title":"EQW + Met","description":"Bydureon EQW + Metformin 1500-2000 mg"},{"id":"OG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Change in times(%): PG<70 baseline to Week 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.19"},{"groupId":"OG001","value":"0.2","spread":"0.19"}]}]},{"title":"Change in times (%): PG <70 baseline to Week 10","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.21"},{"groupId":"OG001","value":"0.1","spread":"0.21"}]}]},{"title":"Change in %: 70 </= PG </=180 baseline to week 4","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":"2.37"},{"groupId":"OG001","value":"4.1","spread":"2.46"}]}]},{"title":"Change in %: 70 </= PG </=180 baseline to week 10","categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":"2.99"},{"groupId":"OG001","value":"1.3","spread":"3.09"}]}]},{"title":"Change in times (%): PG >180 baseline to Week 4","categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"2.37"},{"groupId":"OG001","value":"-4.3","spread":"2.47"}]}]},{"title":"Change in times (%): PG >180 baseline to Week 10","categories":[{"measurements":[{"groupId":"OG000","value":"-22.0","spread":"3.04"},{"groupId":"OG001","value":"-1.4","spread":"3.14"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":".02","timeFrame":"18 weeks","eventGroups":[{"id":"EG000","title":"EQW + Met","description":"Bydureon EQW + Metformin 1500-2000 mg","seriousNumAffected":4,"seriousNumAtRisk":60,"otherNumAffected":35,"otherNumAtRisk":60},{"id":"EG001","title":"Placebo + Met","description":"Placebo + Metformin 1500 + 2000 mg","seriousNumAffected":1,"seriousNumAtRisk":56,"otherNumAffected":26,"otherNumAtRisk":56}],"seriousEvents":[{"term":"Chest Pain","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Non-Cardiac Chest Pain","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Acute Pancreatitis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]}],"otherEvents":[{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":60},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":56}]},{"term":"Bronchitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56}]},{"term":"Vulvovaginal mycotic infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56}]},{"term":"Injection site induration","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56}]},{"term":"Injection site nodule","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Edema peripheral","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Lipase increased","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56}]},{"term":"Amylase increased","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56}]},{"term":"Hyperkalemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56}]},{"term":"Hematuria","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Glycosuria","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Institution \\& PI agree they will not use or disclose and confidential information to third parties for a period of 10 years from receipt."},"pointOfContact":{"title":"Sergey Zhuplatov MD, PhD","organization":"AstraZeneca, PLL","email":"Sergey.Zhuplatov@astrazeneca.com","phone":"215-542-3222"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077270","term":"Exenatide"}],"ancestors":[{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014688","term":"Venoms"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D014118","term":"Toxins, Biological"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true}